EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study

Adriana Palom, Elisabetta Degasperi iD, Barbara Coco, Alessandro Loglio iD, Alessia Ciancio, Grazia Anna Niro, Mar Riveiro-Barciela, Angela Carvalho-Gomes iD, Javier García-Samaniego, Sabela Lens, Ariadna Rando-Segura, Dana Sambarino and 6 more

Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 326-333

DOI: 10.1111/apt.70695 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-04-20. Written by Adriana Palom and 17 co-authors. Institution: Liver Unit, Hospital Univesitari Vall d'Hebron, Barcelona, Spain. Major MEDLINE topics: Liver Cirrhosis, RNA, Viral, Hepatitis Delta Virus, Hepatitis D, Chronic. 17 references. The full text is freely available in PubMed Central. Funded by: Instituto de Salud Carlos III.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Chronic hepatitis D (CHD) is associated with rapid progression to liver cirrhosis. However, the prognostic relevance of quantitative serum HDV‐RNA remains incompletely defined. We aimed to evaluate whether baseline HDV‐RNA levels are associated with the risk of liver‐related events in untreated patients with CHD and to validate these findings in two independent European cohorts.

Methods

We conducted a multicentre retrospective‐prospective cohort study including 260 untreated adults with CHD and detectable HDV‐RNA. Patients were derived from a Spanish derivation cohort ( n = 98) and two Italian validation cohorts ( n = 100 and n = 62). Baseline serum qHDV‐RNA was categorized in 1‐log increments starting from 6 IU/mL.

Results

During a median follow‐up of 4.1 years, 74 patients (28%) experienced at least one liver‐related event, with a significantly higher incidence in patients with cirrhosis than in those without cirrhosis ( p < 0.001). Among noncirrhotic patients, increasing baseline HDV‐RNA levels were consistently associated with a higher proportion of liver‐related events across derivation and validation cohorts, whereas no events occurred at the lowest HDV‐RNA category. In contrast, among patients with established cirrhosis, baseline HDV‐RNA levels were not associated with the occurrence of liver‐related events, and cumulative incidence was comparable across viral load categories.

Conclusions

Baseline quantitative HDV‐RNA allows early risk stratification in untreated patients with chronic hepatitis D before the development of liver cirrhosis. Once cirrhosis is established, clinical outcomes are largely independent of viral replication, emphasising the need to prioritise timely antiviral intervention and close surveillance at earlier disease stages.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisRNA, ViralHepatitis Delta VirusHepatitis D, ChronicHumansFemaleMiddle AgedMaleProspective StudiesAdultRetrospective StudiesDisease ProgressionPrognosisAgedRisk FactorsItalySpain

Author keywords

chronic hepatitis Dcohort validationliver‐related outcomesquantitative HDV‐RNA

Substances

RNA, Viral

Authors and institutions

  • Liver Unit, Hospital Univesitari Vall d'Hebron, Barcelona, Spain.
  • CIBERehd, Madrid, Spain.
  • Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Hepatology Unit, University Hospital, Pisa, Italy.
  • Gastroenterology Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Citta della Salute e della Scienza di Torino (City of Health and Science of Turin), School of Medicine, Department of Medical Sciences, University of Turin Department of Medical Sciences, University of Turin, Turin, Ita…

ORCID profiles: Elisabetta Degasperi, Alessandro Loglio, Angela Carvalho-Gomes, Loretta A Kondili, Mauro Viganò, Pietro Lampertico

Funding

  • Instituto de Salud Carlos III

Cite

APA

Palom, A., Degasperi, E., Coco, B., Loglio, A., Ciancio, A., Niro, G. A., Riveiro-Barciela, M., Carvalho-Gomes, A., García-Samaniego, J., Lens, S., Rando-Segura, A., Sambarino, D., Cotugno, R., Kondili, L. A., Brunetto, M., Viganò, M., Lampertico, P., & Buti, M. (2026). Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study. Alimentary Pharmacology & Therapeutics, 64(3), 326-333. https://doi.org/10.1111/apt.70695

Vancouver

Palom A, Degasperi E, Coco B, Loglio A, Ciancio A, Niro GA, et al. Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study. Alimentary Pharmacology & Therapeutics. 2026;64(3):326-333. doi:10.1111/apt.70695

BibTeX
@article{Palom2026,
  author = {Palom, Adriana and Degasperi, Elisabetta and Coco, Barbara and Loglio, Alessandro and Ciancio, Alessia and Niro, Grazia Anna and Riveiro-Barciela, Mar and Carvalho-Gomes, Angela and García-Samaniego, Javier and Lens, Sabela and Rando-Segura, Ariadna and Sambarino, Dana and Cotugno, Rosa and Kondili, Loretta A and Brunetto, Maurizia and Viganò, Mauro and Lampertico, Pietro and Buti, Maria},
  title = {Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {3},
  pages = {326--333},
  doi = {10.1111/apt.70695}
}
Start for free →